Vanda Pharmaceuticals Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $4.63
- Today's High:
- $4.77
- Open Price:
- $4.69
- 52W Low:
- $4.15
- 52W High:
- $11.0425
- Prev. Close:
- $4.69
- Volume:
- 1341543
Company Statistics
- Market Cap.:
- $268.28 million
- Book Value:
- 9.39
- Revenue TTM:
- $238.35 million
- Operating Margin TTM:
- 4.06%
- Gross Profit TTM:
- $230.10 million
- Profit Margin:
- 6.25%
- Return on Assets TTM:
- 0.97%
- Return on Equity TTM:
- 2.84%
Company Profile
Vanda Pharmaceuticals Inc had its IPO on 2006-04-12 under the ticker symbol VNDA.
The company operates in the Healthcare sector and Biotechnology industry. Vanda Pharmaceuticals Inc has a staff strength of 290 employees.
Stock update
Shares of Vanda Pharmaceuticals Inc opened at $4.69 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $4.63 - $4.77, and closed at $4.66.
This is a -0.64% slip from the previous day's closing price.
A total volume of 1,341,543 shares were traded at the close of the day’s session.
In the last one week, shares of Vanda Pharmaceuticals Inc have slipped by -8.81%.
Vanda Pharmaceuticals Inc's Key Ratios
Vanda Pharmaceuticals Inc has a market cap of $268.28 million, indicating a price to book ratio of 1.1534 and a price to sales ratio of 1.5315.
In the last 12-months Vanda Pharmaceuticals Inc’s revenue was $238.35 million with a gross profit of $230.10 million and an EBITDA of $12.29 million. The EBITDA ratio measures Vanda Pharmaceuticals Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Vanda Pharmaceuticals Inc’s operating margin was 4.06% while its return on assets stood at 0.97% with a return of equity of 2.84%.
In Q2, Vanda Pharmaceuticals Inc’s quarterly earnings growth was a negative -41.9% while revenue growth was a negative 28.5%.
Vanda Pharmaceuticals Inc’s PE and PEG Ratio
- Forward PE
- 30.303
- Trailing PE
- 17.9423
- PEG
- -2.42
Its diluted EPS in the last 12-months stands at $0.26 per share while it has a forward price to earnings multiple of 30.303 and a PEG multiple of -2.42. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Vanda Pharmaceuticals Inc’s profitability.
Vanda Pharmaceuticals Inc stock is trading at a EV to sales ratio of 0.5857 and a EV to EBITDA ratio of 13.5954. Its price to sales ratio in the trailing 12-months stood at 1.5315.
Vanda Pharmaceuticals Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $641.68 million
- Total Liabilities
- $87.40 million
- Operating Cash Flow
- $-190894000.00
- Capital Expenditure
- $55000
- Dividend Payout Ratio
- 0%
Vanda Pharmaceuticals Inc ended 2024 with $641.68 million in total assets and $0 in total liabilities. Its intangible assets were valued at $641.68 million while shareholder equity stood at $539.90 million.
Vanda Pharmaceuticals Inc ended 2024 with $0 in deferred long-term liabilities, $87.40 million in other current liabilities, 57000.00 in common stock, $-153129000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $150.03 million and cash and short-term investments were $489.35 million. The company’s total short-term debt was $2,366,000 while long-term debt stood at $0.
Vanda Pharmaceuticals Inc’s total current assets stands at $533.50 million while long-term investments were $0 and short-term investments were $339.32 million. Its net receivables were $33.62 million compared to accounts payable of $2.17 million and inventory worth $1.08 million.
In 2024, Vanda Pharmaceuticals Inc's operating cash flow was $-190894000.00 while its capital expenditure stood at $55000.
Comparatively, Vanda Pharmaceuticals Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $4.66
- 52-Week High
- $11.0425
- 52-Week Low
- $4.15
- Analyst Target Price
- $7
Vanda Pharmaceuticals Inc stock is currently trading at $4.66 per share. It touched a 52-week high of $11.0425 and a 52-week low of $11.0425. Analysts tracking the stock have a 12-month average target price of $7.
Its 50-day moving average was $5.83 and 200-day moving average was $6.78 The short ratio stood at 4.3 indicating a short percent outstanding of 0%.
Around 406.4% of the company’s stock are held by insiders while 10451.1% are held by institutions.
Frequently Asked Questions About Vanda Pharmaceuticals Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its pipeline products include HETLIOZ (tasimelteon) to treat jet lag disorder, insomnia, delayed sleep phase disorder, sleep disturbances in autism spectrum disorder, and pediatric Non-24; Fanapt (iloperidone) for the treatment of bipolar I disorder and Parkinson’s disease psychosis, as well as a long acting injectable (LAI) formulation to treat schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist to treat gastroparesis, motion sickness, atopic dermatitis, and COVID-19 pneumonia. The company’s pipeline products also include VTR-297, a small molecule histone deacetylase inhibitor to treat hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist to treat performance anxiety and psychiatric disorders; VHX-896, an active metabolite of iloperidone; and antisense oligonucleotide molecules. In addition, it offers a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors that include VSJ-110 for the treatment of dry eye and ocular inflammation; and VPO-227 for the treatment of secretory diarrhea disorders comprising cholera. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.